Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 13.10.2025 1 Ann Vasc Surg 3 BMC Cancer 1 BMJ Case Rep 2 Cancer Med 1 Cancer Res 1 Cancer Sci 1 Cancer Treat Res Commun 1 Case Rep Infect Dis 1 Cell Genom 1 Curr Opin Urol 1 Discov Oncol 3 Eur Urol 2 Eur Urol Oncol 1 Fr J Urol 1 Front Immunol 2 Front Oncol 1 Hum Pathol 1 Int J Med Sci 1 Int J Surg 2 Int J Urol 1 J Coll Physicians Surg Pak 2 J Urol 2 Jpn J Radiol 1 MedComm (2020) 1 MMW Fortschr Med 1 Mol Oncol 1 Res Rep Urol 1 Sci Rep 1 Skin Res Technol 1 Urol Oncol 1 Urol Pract 2 World J Urol 1 Zhonghua Bing Li Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Vasc Surg

1. COLONNA G, Liesker D, M WB, Taurino M, et al
   Clinical Characteristics and Management of Infective Native Arterial Aneurysms Associated with BCG Therapy for Bladder Cancer.
   Ann Vasc Surg. 2025 Oct 8:S0890-5096(25)00659-4. doi: 10.1016/j.avsg.2025.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al
   Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.
   BMC Cancer. 2025;25:1524.
   PubMed         Abstract available
   
   
3. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al
   Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.
   BMC Cancer. 2025;25:1525.
   PubMed         Abstract available
   
   
4. YEH CC, Tsai PC, Song YD, Low YS, et al
   Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model.
   BMC Cancer. 2025;25:1534.
   PubMed         Abstract available
   
   

   
   BMJ Case Rep

5. HUSSAIN H, Reid U, Nagtode S, Shameem F, et al
   Macroplastique, a urethral bulking agent for stress urinary incontinence mimicking a bladder tumour.
   BMJ Case Rep. 2025;18:e263166.
   PubMed         Abstract available
   
   

   
   Cancer Med

6. MEYERS HM, Sharma J, Abdellatef AA, You M, et al
   Differential Expression of One-Carbon Pathway Enzyme ALDH1L1 Is Linked to Tumorigenicity of Low-Grade Bladder Cancer Cells Through Metabolic Reprogramming.
   Cancer Med. 2025;14:e71291.
   PubMed         Abstract available
   
   
7. WANG S, Ye D, Yang L, Cheng F, et al
   Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.
   Cancer Med. 2025;14:e71289.
   PubMed         Abstract available
   
   

   
   Cancer Res

8. WU J, Cheng B, Song Y, Cheng J, et al
   Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
   Cancer Res. 2025 Oct 9. doi: 10.1158/0008-5472.CAN-25-0024.
   PubMed         Abstract available
   
   

   
   Cancer Sci

9. SUGINO Y, Bao X, Sekito S, Miyachi S, et al
   Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive Bladder Cancer.
   Cancer Sci. 2025 Oct 8. doi: 10.1111/cas.70217.
   PubMed         Abstract available
   
   

   
   Cancer Treat Res Commun

10. MOHAMMADNEJAD F, Rajabi N, Doustvandi MA, Nobari SA, et al
    Photodynamic therapy with zinc phthalocyanine enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by downregulation of PI3K/AKT/mTOR signaling pathway.
    Cancer Treat Res Commun. 2025;45:101007.
    PubMed         Abstract available
    
    

    
    Case Rep Infect Dis

11. MARTINSON T, Hare CB, Kirmaier A, Presti JC, et al
    Disseminated BCGosis After Intravesical BCG Installation for Bladder Cancer.
    Case Rep Infect Dis. 2025;2025:9532859.
    PubMed         Abstract available
    
    

    
    Cell Genom

12. LOTEM M, Sharkia I, Azria B, Harpenas E, et al
    Urine cf-nucleosomes: A non-invasive window into human physiology and disease.
    Cell Genom. 2025;5:100974.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

13. PRADERE B, Schuit M, Guerrero-Ramos F, Shariat SF, et al
    Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
    Curr Opin Urol. 2025 Oct 8. doi: 10.1097/MOU.0000000000001350.
    PubMed         Abstract available
    
    

    
    Discov Oncol

14. MA Z, Hao Y, He W, Xie X, et al
    Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer.
    Discov Oncol. 2025;16:1847.
    PubMed         Abstract available
    
    

    
    Eur Urol

15. KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al
    Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Can
    Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145.
    PubMed         Abstract available
    
    
16. MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al
    Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.
    Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138.
    PubMed         Abstract available
    
    
17. DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al
    Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.
    Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

18. MOLINA-CERRILLO J, Catto J, Kamat AM, Necchi A, et al
    Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2025 Oct 8:S2588-9311(25)00242-1. doi: 10.1016/j.euo.2025.
    PubMed         Abstract available
    
    
19. RADIF D, Lindskrog SV, Nordentoft I, Birkenkamp-Demtroder K, et al
    The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2025 Oct 9:S2588-9311(25)00246-9. doi: 10.1016/j.euo.2025.
    PubMed         Abstract available
    
    

    
    Fr J Urol

20. BROUZES H, Ourfali S, Fassi-Fehri H, Benoit-Janin M, et al
    Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach.
    Fr J Urol. 2025;35:102921.
    PubMed         Abstract available
    
    

    
    Front Immunol

21. DULF DV, Ravegnini G, Giorgi FM, Burnar AL, et al
    The miRNA-immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision.
    Front Immunol. 2025;16:1639334.
    PubMed         Abstract available
    
    

    
    Front Oncol

22. GUI Q, Guo H, Liu T, Wen X, et al
    Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer.
    Front Oncol. 2025;15:1646723.
    PubMed         Abstract available
    
    
23. ZHANG L, Li F, Liu L, Cao J, et al
    Prevalence and prognostic value of sarcopenia in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2025;15:1642833.
    PubMed         Abstract available
    
    

    
    Hum Pathol

24. IIZUKA T, Ishikawa A, Motoi N, Kanda H, et al
    Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions.
    Hum Pathol. 2025;160:105823.
    PubMed         Abstract available
    
    

    
    Int J Med Sci

25. CHOU KY, Chang AC, Hwang TI, Tsai TF, et al
    ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer.
    Int J Med Sci. 2025;22:3895-3905.
    PubMed         Abstract available
    
    

    
    Int J Surg

26. TONG H, Sun Y, He W
    Commentary on "Complex causal association between immune cell phenotypes and bladder cancer: a mendelian randomization and mediation study".
    Int J Surg. 2025 Oct 7. doi: 10.1097/JS9.0000000000003587.
    PubMed        
    
    

    
    Int J Urol

27. AKPINAR C, Erkartal S, Soydas T, Demirel D, et al
    Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.
    Int J Urol. 2025;32:1395-1402.
    PubMed         Abstract available
    
    
28. INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al
    Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
    Int J Urol. 2025;32:1449-1459.
    PubMed         Abstract available
    
    

    
    J Coll Physicians Surg Pak

29. MAQBOOL A, Aziz W, Iqbal S, Ather MH, et al
    Effectiveness of Video-Based Instructions on Urostomy Self-Care in Patients Undergoing Radical Cystectomy with Ileal Conduit Urinary Diversion.
    J Coll Physicians Surg Pak. 2025;35:1345-1349.
    PubMed         Abstract available
    
    

    
    J Urol

30. DONAHUE TF, Assel M, Cha EK, Goh A, et al
    Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
    J Urol. 2025;214:487-495.
    PubMed         Abstract available
    
    
31. MEEKS JJ, van der Heijden MS, Powles T, Galsky MD, et al
    PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
    J Urol. 2025;214:556.
    PubMed        
    
    

    
    Jpn J Radiol

32. ITO H, Koyama T, Tanahara S, Toda D, et al
    MRI findings of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin treatment for bladder cancer: a comparison with prostate cancer.
    Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01871.
    PubMed         Abstract available
    
    
33. TOKUDA PJK, Aizawa R, Iramina H, Ogata T, et al
    Online adaptive radiation therapy for muscle-invasive bladder cancer: short-course and high-precision definitive treatment for elderly or medically fragile patients.
    Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01885.
    PubMed         Abstract available
    
    

    
    MedComm (2020)

34. LIU H, Chen J, Zhu Q, Liu H, et al
    Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.
    MedComm (2020). 2025;6:e70427.
    PubMed        
    
    

    
    MMW Fortschr Med

35. KIDESS M, Ebner B, Volz Y, Hermans J, et al
    [Therapy of non-muscle-invasive Bladder Cancer].
    MMW Fortschr Med. 2025;167:40-41.
    PubMed        
    
    

    
    Mol Oncol

36. PECE A, Lovato G, Cela I, Mercatelli A, et al
    Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.
    Mol Oncol. 2025 Oct 5. doi: 10.1002/1878-0261.70140.
    PubMed         Abstract available
    
    

    
    Res Rep Urol

37. DI Y, Zhang L, Zhao L, Yin L, et al
    Influencing Factors and Risk Prediction Model Construction of Urinary Tract Infections in Patients with Bladder Cancer.
    Res Rep Urol. 2025;17:383-399.
    PubMed         Abstract available
    
    

    
    Sci Rep

38. CELIK M, Polat ME, Karaaslan M, Odabas O, et al
    Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer.
    Sci Rep. 2025;15:35415.
    PubMed         Abstract available
    
    

    
    Skin Res Technol

39. 
    RETRACTION: Examining the Causal Association between Psoriasis and Bladder Cancer: A Two-sample Mendelian Randomization Analysis.
    Skin Res Technol. 2025;31:e70252.
    PubMed        
    
    

    
    Urol Oncol

40. CHEN AL, Zhang CA, Ogunkeye J, Ge TJ, et al
    Differences in postoperative communication patterns among patients with limited English proficiency following radical cystectomy for bladder cancer.
    Urol Oncol. 2025 Oct 3:S1078-1439(25)00346-1. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    

    
    Urol Pract

41. ZHANG EZ, Millot JC, Balasubramanian A, Davis L, et al
    Persistent Sex Disparities in Bladder Cancer Diagnosis, an Analysis of National Trends from 2012 to 2021.
    Urol Pract. 2025 Oct 10:101097UPJ0000000000000904.
    PubMed         Abstract available
    
    

    
    World J Urol

42. KAWAHARA T, Nitta S, Shiga M, Nagumo Y, et al
    Second opinions and pathological review impact the clinical management of patients with muscle-invasive bladder cancer.
    World J Urol. 2025;43:602.
    PubMed         Abstract available
    
    
43. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients.
    World J Urol. 2025;43:591.
    PubMed         Abstract available
    
    

    
    Zhonghua Bing Li Xue Za Zhi

44. MA TS, He HY
    [The application and advances of immunohistochemistry in the diagnosis and differential diagnosis of bladder tumors].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:1110-1113.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.